Literature DB >> 19269138

Risk/reward decision-making in schizophrenia: a preliminary examination of the influence of tobacco smoking and relationship to Wisconsin Card Sorting Task performance.

Sarah W Yip1, Kristi A Sacco, Tony P George, Marc N Potenza.   

Abstract

BACKGROUND: Individuals with schizophrenia show deficits in cognitive functioning, as evidenced by deficits on neurocognitive tasks such as the Wisconsin Card Sorting Task (WCST). Studies of risk/reward decision-making in individuals with schizophrenia have yielded mixed results, and few studies have examined systematically the relationship between these domains and their relationship with clinical factors.
METHOD: Thirty-two smokers with schizophrenia, ten non-smokers with schizophrenia, nine non-psychiatric non-smokers and ten non-psychiatric smokers were administered computerized versions of the Iowa Gambling Task (IGT) and the WCST. Smokers were allowed to smoke adlibitum during designated breaks in order to prevent deprivation.
RESULTS: Subjects with schizophrenia performed significantly worse than non-psychiatric controls on both the IGT and the WCST, and performance on these tasks was significantly correlated across subject groups. Among women with schizophrenia, smokers performed significantly better than non-smokers on the IGT.
CONCLUSIONS: Individuals with schizophrenia perform worse than controls on the IGT, suggesting impairments in risk/reward decision-making. Correlations between IGT and WCST performance suggest a shared element underlying task performance, such as a deficit in set-shifting or perseverance. Further research is needed to establish the relationship between cigarette smoking and IGT performance in schizophrenia.

Entities:  

Mesh:

Year:  2009        PMID: 19269138      PMCID: PMC2817985          DOI: 10.1016/j.schres.2009.01.012

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  45 in total

1.  Decision-making impairments in adolescents with early-onset schizophrenia.

Authors:  Hana M Kester; Serge Sevy; Eldad Yechiam; Katherine E Burdick; Kelly L Cervellione; Sanjiv Kumra
Journal:  Schizophr Res       Date:  2006-06-02       Impact factor: 4.939

2.  Prefrontal cognitive functions in stabilized first-episode patients with schizophrenia spectrum disorders: a dissociation between dorsolateral and orbitofrontal functioning.

Authors:  José Manuel Rodríguez-Sánchez; Benedicto Crespo-Facorro; Rocío Perez-Iglesias; Rocío Perez Iglesias; César González-Blanch; César González-Blanch Bosch; Mario Alvarez-Jimenez; Mario Alvarez; Javier Llorca; José Luis Vázquez-Barquero
Journal:  Schizophr Res       Date:  2005-09-15       Impact factor: 4.939

3.  Physiological activation of a cortical network during performance of the Wisconsin Card Sorting Test: a positron emission tomography study.

Authors:  K F Berman; J L Ostrem; C Randolph; J Gold; T E Goldberg; R Coppola; R E Carson; P Herscovitch; D R Weinberger
Journal:  Neuropsychologia       Date:  1995-08       Impact factor: 3.139

4.  Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms.

Authors:  Kristi A Sacco; Angelo Termine; Aisha Seyal; Melissa M Dudas; Jennifer C Vessicchio; Suchitra Krishnan-Sarin; Peter I Jatlow; Bruce E Wexler; Tony P George
Journal:  Arch Gen Psychiatry       Date:  2005-06

5.  Schizophrenia patients demonstrate a distinctive pattern of decision-making impairment on the Iowa Gambling Task.

Authors:  Brett Shurman; William P Horan; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2005-01-01       Impact factor: 4.939

6.  Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. II. Role of neuroleptic treatment, attention, and mental effort.

Authors:  K F Berman; R F Zec; D R Weinberger
Journal:  Arch Gen Psychiatry       Date:  1986-02

7.  Typical and atypical antipsychotic medications differentially affect two nondeclarative memory tasks in schizophrenic patients: a double dissociation.

Authors:  Richard J Beninger; James Wasserman; Katherine Zanibbi; Danielle Charbonneau; Jennifer Mangels; Bruce V Beninger
Journal:  Schizophr Res       Date:  2003-06-01       Impact factor: 4.939

8.  Regional cerebral blood flow during the Wisconsin Card Sorting Test in normal subjects studied by xenon-133 dynamic SPECT: comparison of absolute values, percent distribution values, and covariance analysis.

Authors:  S Marenco; R Coppola; D G Daniel; J R Zigun; D R Weinberger
Journal:  Psychiatry Res       Date:  1993-10       Impact factor: 3.222

9.  Dissociation of emotional decision-making from cognitive decision-making in chronic schizophrenia.

Authors:  Yanghyun Lee; Yang-Tae Kim; Eugene Seo; Oaktae Park; Sung-Hun Jeong; Sang Heon Kim; Seung-Jae Lee
Journal:  Psychiatry Res       Date:  2007-04-25       Impact factor: 3.222

10.  Orbitofrontal volume deficit in schizophrenia and thought disorder.

Authors:  Motoaki Nakamura; Paul G Nestor; James J Levitt; Adam S Cohen; Toshiro Kawashima; Martha E Shenton; Robert W McCarley
Journal:  Brain       Date:  2007-12-03       Impact factor: 13.501

View more
  18 in total

Review 1.  Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions.

Authors:  Deanna M Barch; Erin C Dowd
Journal:  Schizophr Bull       Date:  2010-06-21       Impact factor: 9.306

Review 2.  Negative affective states and cognitive impairments in nicotine dependence.

Authors:  F Scott Hall; Andre Der-Avakian; Thomas J Gould; Athina Markou; Mohammed Shoaib; Jared W Young
Journal:  Neurosci Biobehav Rev       Date:  2015-06-06       Impact factor: 8.989

3.  Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis.

Authors:  Lisa Buchy; Larry J Seidman; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; William Stone; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Daniel H Mathalon; Jean Addington
Journal:  Psychiatry Res       Date:  2015-11-25       Impact factor: 3.222

Review 4.  The utility of rat models of impulsivity in developing pharmacotherapies for impulse control disorders.

Authors:  Catharine A Winstanley
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

5.  Cigarette smoking modulates medication-associated deficits in a monetary reward task in patients with schizophrenia.

Authors:  Birgit Lernbass; Georg Grön; Nadine D Wolf; Birgit Abler
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-09-26       Impact factor: 5.270

6.  Effects of disrupting medial prefrontal cortex GABA transmission on decision-making in a rodent gambling task.

Authors:  T A Paine; A O'Hara; B Plaut; D C Lowes
Journal:  Psychopharmacology (Berl)       Date:  2014-11-26       Impact factor: 4.530

7.  A further evaluation of decision-making under risk and under ambiguity in schizophrenia.

Authors:  Guillaume Fond; Sophie Bayard; Delphine Capdevielle; Jonathan Del-Monte; Nawale Mimoun; Alexandra Macgregor; Jean-Philippe Boulenger; Marie-Christine Gely-Nargeot; Stéphane Raffard
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-05-26       Impact factor: 5.270

Review 8.  The motivation and pleasure dimension of negative symptoms: neural substrates and behavioral outputs.

Authors:  Ann M Kring; Deanna M Barch
Journal:  Eur Neuropsychopharmacol       Date:  2014-01-22       Impact factor: 4.600

9.  Prefrontal cognitive dysfunction is associated with tobacco dependence treatment failure in smokers with schizophrenia.

Authors:  Taryn G Moss; Kristi A Sacco; Taryn M Allen; Andrea H Weinberger; Jennifer C Vessicchio; Tony P George
Journal:  Drug Alcohol Depend       Date:  2009-05-17       Impact factor: 4.492

10.  Medial prefrontal cortex lesions impair decision-making on a rodent gambling task: reversal by D1 receptor antagonist administration.

Authors:  Tracie A Paine; Samuel K Asinof; Geoffrey W Diehl; Anna Frackman; Joseph Leffler
Journal:  Behav Brain Res       Date:  2013-01-24       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.